A. Dursun Et Al. , "National safety data of post-marketing use of omalizumab in severe persistent asthma in Turkey," 30th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , vol.66, İstanbul, Turkey, pp.675-676, 2011
Dursun, A. Et Al. 2011. National safety data of post-marketing use of omalizumab in severe persistent asthma in Turkey. 30th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , (İstanbul, Turkey), 675-676.
Dursun, A., Bavbek, S., Misirligil, Z., Erdener, F., Buyukozturk, S., Aydin, O., ... Gemicioglu, B.(2011). National safety data of post-marketing use of omalizumab in severe persistent asthma in Turkey . 30th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) (pp.675-676). İstanbul, Turkey
Dursun, A. Et Al. "National safety data of post-marketing use of omalizumab in severe persistent asthma in Turkey," 30th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), İstanbul, Turkey, 2011
Dursun, A. Et Al. "National safety data of post-marketing use of omalizumab in severe persistent asthma in Turkey." 30th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , İstanbul, Turkey, pp.675-676, 2011
Dursun, A. Et Al. (2011) . "National safety data of post-marketing use of omalizumab in severe persistent asthma in Turkey." 30th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , İstanbul, Turkey, pp.675-676.
@conferencepaper{conferencepaper, author={A. Dursun Et Al. }, title={National safety data of post-marketing use of omalizumab in severe persistent asthma in Turkey}, congress name={30th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI)}, city={İstanbul}, country={Turkey}, year={2011}, pages={675-676} }